Neuren Pharmaceutical's partner Acadia reports boosted sales of the Rett syndrome drug Daybue, but Neuren notes two-thirds of ...

People with a wheat or soy allergy could experience a "serious or life-threatening" reaction if they consume the product.

Key Points Non-GAAP earnings per share (EPS) of $2.25 in Q2 2025 far surpassed the analyst estimate of $0.32 and rose 923% year-over-year compared to Q2 2024 (non-GAAP adjusted diluted EPS per ADS).

For instructions on how to access the free Hawaiʻi Medical Cannabis Course Bundle, click here.

The first aceclidine-based eye drop to improve near vision in adults with presbyopia, which affects more than 100 million ...

A Rankin County teenager’s life-changing medication is being denied approval by the U.S. Food and Drug Administration, leaving him and many others with rare diseases unsure of their futures.

- Robert Foster will serve as Acting General Counsel at HHS, maintaining his role as FDA Chief Counsel for Food, Research, ...

In a letter to physicians, the company noted that there is an increased risk of blockages in the bloodstream depending on the ...

CMS often withholds coverage for reimbursement, disrupting the natural flow of the market and hindering access to proven ...

By going after an obscure regulatory designation he describes as a “loophole,” Mr. Kennedy has put an industry he champions ...